Transcranial magnetic stimulation of the brain: Guidelines for pain treatment research

Max M. Klein, Roi Treister, Tommi Raij, Alvaro Pascual-Leone, Lawrence Park, Turo Nurmikko, Frederick Lenz, Jean Pascal Lefaucheur, Magdalena Lang, Mark Hallett, Michael Fox, Merit Cudkowicz, Ann Costello, Daniel B. Carr, Samar S. Ayache, Anne Louise Oaklander

Research output: Contribution to journalArticle

Abstract

Recognizing that electrically stimulating the motor cortex could relieve chronic pain sparked development of noninvasive technologies. In transcranial magnetic stimulation (TMS), electromagnetic coils held against the scalp influence underlying cortical firing. Multiday repetitive transcranial magnetic stimulation (rTMS) can induce long-lasting, potentially therapeutic brain plasticity. Nearby ferromagnetic or electronic implants are contraindications. Adverse effects are minimal, primarily headaches. Single provoked seizures are very rare. Transcranial magnetic stimulation devices are marketed for depression and migraine in the United States and for various indications elsewhere. Although multiple studies report that high-frequency rTMS of the motor cortex reduces neuropathic pain, their quality has been insufficient to support Food and Drug Administration application. Harvard's Radcliffe Institute therefore sponsored a workshop to solicit advice from experts in TMS, pain research, and clinical trials. They recommended that researchers standardize and document all TMS parameters and improve strategies for sham and double blinding. Subjects should have common well-characterized pain conditions amenable to motor cortex rTMS and studies should be adequately powered. They recommended standardized assessment tools (eg, NIH's PROMIS) plus validated condition-specific instruments and consensus-recommended metrics (eg, IMMPACT). Outcomes should include pain intensity and qualities, patient and clinician impression of change, and proportions achieving 30% and 50% pain relief. Secondary outcomes could include function, mood, sleep, and/or quality of life. Minimum required elements include sample sources, sizes, and demographics, recruitment methods, inclusion and exclusion criteria, baseline and posttreatment means and SD, adverse effects, safety concerns, discontinuations, and medication-usage records. Outcomes should be monitored for at least 3 months after initiation with prespecified statistical analyses. Multigroup collaborations or registry studies may be needed for pivotal trials.

Original languageEnglish (US)
Pages (from-to)1601-1614
Number of pages14
JournalPain
Volume156
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Transcranial Magnetic Stimulation
Guidelines
Pain
Brain
Research
Motor Cortex
Therapeutics
Electromagnetic Phenomena
Neuralgia
United States Food and Drug Administration
Scalp
Migraine Disorders
Chronic Pain
Sample Size
Headache
Registries
Epilepsy
Consensus
Sleep
Quality of Life

Keywords

  • Device
  • Human
  • Neuromodulation
  • Neuropathic pain
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine
  • Neurology
  • Pharmacology

Cite this

Klein, M. M., Treister, R., Raij, T., Pascual-Leone, A., Park, L., Nurmikko, T., ... Oaklander, A. L. (2015). Transcranial magnetic stimulation of the brain: Guidelines for pain treatment research. Pain, 156(9), 1601-1614. https://doi.org/10.1097/j.pain.0000000000000210

Transcranial magnetic stimulation of the brain : Guidelines for pain treatment research. / Klein, Max M.; Treister, Roi; Raij, Tommi; Pascual-Leone, Alvaro; Park, Lawrence; Nurmikko, Turo; Lenz, Frederick; Lefaucheur, Jean Pascal; Lang, Magdalena; Hallett, Mark; Fox, Michael; Cudkowicz, Merit; Costello, Ann; Carr, Daniel B.; Ayache, Samar S.; Oaklander, Anne Louise.

In: Pain, Vol. 156, No. 9, 01.09.2015, p. 1601-1614.

Research output: Contribution to journalArticle

Klein, MM, Treister, R, Raij, T, Pascual-Leone, A, Park, L, Nurmikko, T, Lenz, F, Lefaucheur, JP, Lang, M, Hallett, M, Fox, M, Cudkowicz, M, Costello, A, Carr, DB, Ayache, SS & Oaklander, AL 2015, 'Transcranial magnetic stimulation of the brain: Guidelines for pain treatment research', Pain, vol. 156, no. 9, pp. 1601-1614. https://doi.org/10.1097/j.pain.0000000000000210
Klein MM, Treister R, Raij T, Pascual-Leone A, Park L, Nurmikko T et al. Transcranial magnetic stimulation of the brain: Guidelines for pain treatment research. Pain. 2015 Sep 1;156(9):1601-1614. https://doi.org/10.1097/j.pain.0000000000000210
Klein, Max M. ; Treister, Roi ; Raij, Tommi ; Pascual-Leone, Alvaro ; Park, Lawrence ; Nurmikko, Turo ; Lenz, Frederick ; Lefaucheur, Jean Pascal ; Lang, Magdalena ; Hallett, Mark ; Fox, Michael ; Cudkowicz, Merit ; Costello, Ann ; Carr, Daniel B. ; Ayache, Samar S. ; Oaklander, Anne Louise. / Transcranial magnetic stimulation of the brain : Guidelines for pain treatment research. In: Pain. 2015 ; Vol. 156, No. 9. pp. 1601-1614.
@article{7531e7e021d14a0c89d83b448f2b54d3,
title = "Transcranial magnetic stimulation of the brain: Guidelines for pain treatment research",
abstract = "Recognizing that electrically stimulating the motor cortex could relieve chronic pain sparked development of noninvasive technologies. In transcranial magnetic stimulation (TMS), electromagnetic coils held against the scalp influence underlying cortical firing. Multiday repetitive transcranial magnetic stimulation (rTMS) can induce long-lasting, potentially therapeutic brain plasticity. Nearby ferromagnetic or electronic implants are contraindications. Adverse effects are minimal, primarily headaches. Single provoked seizures are very rare. Transcranial magnetic stimulation devices are marketed for depression and migraine in the United States and for various indications elsewhere. Although multiple studies report that high-frequency rTMS of the motor cortex reduces neuropathic pain, their quality has been insufficient to support Food and Drug Administration application. Harvard's Radcliffe Institute therefore sponsored a workshop to solicit advice from experts in TMS, pain research, and clinical trials. They recommended that researchers standardize and document all TMS parameters and improve strategies for sham and double blinding. Subjects should have common well-characterized pain conditions amenable to motor cortex rTMS and studies should be adequately powered. They recommended standardized assessment tools (eg, NIH's PROMIS) plus validated condition-specific instruments and consensus-recommended metrics (eg, IMMPACT). Outcomes should include pain intensity and qualities, patient and clinician impression of change, and proportions achieving 30{\%} and 50{\%} pain relief. Secondary outcomes could include function, mood, sleep, and/or quality of life. Minimum required elements include sample sources, sizes, and demographics, recruitment methods, inclusion and exclusion criteria, baseline and posttreatment means and SD, adverse effects, safety concerns, discontinuations, and medication-usage records. Outcomes should be monitored for at least 3 months after initiation with prespecified statistical analyses. Multigroup collaborations or registry studies may be needed for pivotal trials.",
keywords = "Device, Human, Neuromodulation, Neuropathic pain, Treatment",
author = "Klein, {Max M.} and Roi Treister and Tommi Raij and Alvaro Pascual-Leone and Lawrence Park and Turo Nurmikko and Frederick Lenz and Lefaucheur, {Jean Pascal} and Magdalena Lang and Mark Hallett and Michael Fox and Merit Cudkowicz and Ann Costello and Carr, {Daniel B.} and Ayache, {Samar S.} and Oaklander, {Anne Louise}",
year = "2015",
month = "9",
day = "1",
doi = "10.1097/j.pain.0000000000000210",
language = "English (US)",
volume = "156",
pages = "1601--1614",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Transcranial magnetic stimulation of the brain

T2 - Guidelines for pain treatment research

AU - Klein, Max M.

AU - Treister, Roi

AU - Raij, Tommi

AU - Pascual-Leone, Alvaro

AU - Park, Lawrence

AU - Nurmikko, Turo

AU - Lenz, Frederick

AU - Lefaucheur, Jean Pascal

AU - Lang, Magdalena

AU - Hallett, Mark

AU - Fox, Michael

AU - Cudkowicz, Merit

AU - Costello, Ann

AU - Carr, Daniel B.

AU - Ayache, Samar S.

AU - Oaklander, Anne Louise

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Recognizing that electrically stimulating the motor cortex could relieve chronic pain sparked development of noninvasive technologies. In transcranial magnetic stimulation (TMS), electromagnetic coils held against the scalp influence underlying cortical firing. Multiday repetitive transcranial magnetic stimulation (rTMS) can induce long-lasting, potentially therapeutic brain plasticity. Nearby ferromagnetic or electronic implants are contraindications. Adverse effects are minimal, primarily headaches. Single provoked seizures are very rare. Transcranial magnetic stimulation devices are marketed for depression and migraine in the United States and for various indications elsewhere. Although multiple studies report that high-frequency rTMS of the motor cortex reduces neuropathic pain, their quality has been insufficient to support Food and Drug Administration application. Harvard's Radcliffe Institute therefore sponsored a workshop to solicit advice from experts in TMS, pain research, and clinical trials. They recommended that researchers standardize and document all TMS parameters and improve strategies for sham and double blinding. Subjects should have common well-characterized pain conditions amenable to motor cortex rTMS and studies should be adequately powered. They recommended standardized assessment tools (eg, NIH's PROMIS) plus validated condition-specific instruments and consensus-recommended metrics (eg, IMMPACT). Outcomes should include pain intensity and qualities, patient and clinician impression of change, and proportions achieving 30% and 50% pain relief. Secondary outcomes could include function, mood, sleep, and/or quality of life. Minimum required elements include sample sources, sizes, and demographics, recruitment methods, inclusion and exclusion criteria, baseline and posttreatment means and SD, adverse effects, safety concerns, discontinuations, and medication-usage records. Outcomes should be monitored for at least 3 months after initiation with prespecified statistical analyses. Multigroup collaborations or registry studies may be needed for pivotal trials.

AB - Recognizing that electrically stimulating the motor cortex could relieve chronic pain sparked development of noninvasive technologies. In transcranial magnetic stimulation (TMS), electromagnetic coils held against the scalp influence underlying cortical firing. Multiday repetitive transcranial magnetic stimulation (rTMS) can induce long-lasting, potentially therapeutic brain plasticity. Nearby ferromagnetic or electronic implants are contraindications. Adverse effects are minimal, primarily headaches. Single provoked seizures are very rare. Transcranial magnetic stimulation devices are marketed for depression and migraine in the United States and for various indications elsewhere. Although multiple studies report that high-frequency rTMS of the motor cortex reduces neuropathic pain, their quality has been insufficient to support Food and Drug Administration application. Harvard's Radcliffe Institute therefore sponsored a workshop to solicit advice from experts in TMS, pain research, and clinical trials. They recommended that researchers standardize and document all TMS parameters and improve strategies for sham and double blinding. Subjects should have common well-characterized pain conditions amenable to motor cortex rTMS and studies should be adequately powered. They recommended standardized assessment tools (eg, NIH's PROMIS) plus validated condition-specific instruments and consensus-recommended metrics (eg, IMMPACT). Outcomes should include pain intensity and qualities, patient and clinician impression of change, and proportions achieving 30% and 50% pain relief. Secondary outcomes could include function, mood, sleep, and/or quality of life. Minimum required elements include sample sources, sizes, and demographics, recruitment methods, inclusion and exclusion criteria, baseline and posttreatment means and SD, adverse effects, safety concerns, discontinuations, and medication-usage records. Outcomes should be monitored for at least 3 months after initiation with prespecified statistical analyses. Multigroup collaborations or registry studies may be needed for pivotal trials.

KW - Device

KW - Human

KW - Neuromodulation

KW - Neuropathic pain

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84964655342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964655342&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000000210

DO - 10.1097/j.pain.0000000000000210

M3 - Article

C2 - 25919472

AN - SCOPUS:84964655342

VL - 156

SP - 1601

EP - 1614

JO - Pain

JF - Pain

SN - 0304-3959

IS - 9

ER -